SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a wild run-up, leading to multiple trading halts, and the community is debating whether to hold through after-hours for potential gains. Some traders believe a short squeeze is in play, while others are wary of a potential pullback. The stock's volatility and low float are key discussion points.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix ($NFLX) is trending amid speculation about a potential acquisition of Warner Bros. Discovery ($WBD), with recent price action reflecting market uncertainty and deal complexities. Community discussions revolve around the potential outcomes of the acquisition, including concerns about debt and market competition, as well as alternative scenarios where Netflix remains independent.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders digest the Fed's latest moves, including a rate cut and plans for Treasury bill purchases, sparking debates about whether this signals renewed easing and its impact on inflation. The community is actively discussing potential market direction, with bulls citing continued economic strength and bears pointing to labor market weakness and potential risks. Many traders are closely watching for a potential run to new all-time highs.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid expectations surrounding the Fed's rate decision and commentary on future monetary policy, with potential implications for AI spending. Community members are actively discussing possible market reactions and impacts of a rate cut, and some express concerns about the Fed's influence. Traders are closely watching key levels and anticipating volatility, while also debating the influence of AI on the economy.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group (MIGI) is trending due to anticipation surrounding its presentation at the Emerging Growth Conference, with discussions focusing on its growth strategy in bitcoin mining and AI infrastructure. Community members are actively speculating on potential catalysts from the conference, particularly updates on contracts and corporate developments. With a tiny float, MIGI is also recognized for its volatility and potential for explosive moves, especially given its expansion into power capacity, colocation services, and AI/GPU hosting pilots.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders discuss the potential for new all-time highs amid a possible rotation into small caps and anticipation surrounding the upcoming Fed meeting and potential rate cuts. Community members are actively trading options, with bullish and bearish sentiment reflected in discussions around calls and puts, while the index flirts with resistance levels. Some analysts suggest that small caps may outperform in 2026, while others express concern about a potential pullback.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana ($CVNA) is trending as traders debate its extreme valuation and potential for a short squeeze amid S&P 500 inclusion. Community chatter highlights the stock's unusual price action, comparisons to meme stocks, and concerns about potential fraud. The availability of shares to short is also a hot topic, with many platforms reportedly restricting short positions.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending amid speculation about an earnings leak and a potential AI-driven surge, with significant options activity suggesting a large move is expected. Community discussions revolve around whether Oracle can validate its AI investments and the broader implications for the AI market. Some traders are betting on a positive earnings report to fuel a rally, while others remain cautious, citing concerns about debt and overvaluation.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals (BDRX) is trending as traders discuss its potential for a squeeze, citing its low float and the past performance of similar stocks. Community members are actively monitoring price movements and debating entry/exit strategies. Some traders are pointing to catalysts while others warn of potential dilution.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending with mixed sentiment as investors weigh the potential of AI investments against immediate returns; the stock's underperformance compared to its peers in the Magnificent Seven is fueling frustration. Community discussions include concerns about Microsoft's AI strategy and its impact on the company's value, while some are looking for bargain opportunities as the broader market rallies. Additionally, a new partnership with Lockheed Martin to launch an AI-driven counter-UAS platform has surfaced.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Groupon, BriaCell Therapeutics, and InnovAge shine as Zacks' top November picks for powerful earnings acceleration potential.

Top 3 Earnings Acceleration Buys for November 

Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches. 

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of BriaCell Therapeutics Corp (BCTX) fell over 8% in Thursday's after-hours trading as the Canadian biotech firm priced a public offering of about $13.8 million.&nbsp;Retail investors, however, were focused on positive catalysts from earlier in the day.The West Vancouver, Canada-based company said it is issuing over 3 million shares at $4.50 apiece, more than 25% lower from the last closing price.The offer includes nearly 400,000 units sold through the full exercise of the underwriter's option.Each unit has one common share (or a pre-funded warrant) and one tradeable warrant.&nbsp;BriaCell expects to close the offering on April 28, pending customary closing conditions, and will use the proceeds for working capital, corporate purposes, and advancing its immunotherapy programs.Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis, first reported in February 2025, now confirmed at the four-month mark. The news sent the stock up more than 11% in the regular session.The 78-year-old woman with metastatic breast cancer had previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bctx-stock-climbs-after-bria-ots-resolves-cancer-metastasis/chPYRuVRAQ">failed</a> several lines of therapy and received the lowest dose level in the study.Upon enrollment in November 2024, the patient had widespread disease, including lung, lymph node, and bone metastases.&nbsp;After receiving Bria-OTS injections every two weeks for six weeks, then every three weeks, her lung metastasis fully resolved, and stable disease has been maintained elsewhere in the body.On Stocktwits, the clinical news took precedence as sentiment for BriaCell turned even more 'extremely bullish' late Thursday amid a 1,266% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BCTX_sentiment_and_message_volume_as_of_April_24_png_c4da18642c.webp" alt="BCTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>BCTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>"This is THE most undervalued biotech on NASDAQ, and that will be proven in coming months," posted one user.<stembedurl>https://stocktwits.com/Fvalstounge/message/612629738</stembedurl>"This company should be worth several billion dollars... WOW," wrote another.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/61253769</stembedurl>BriaCell stock, however, has lost over 82% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.

Equity

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.


Nasdaq-listed shares of BriaCell Therapeutics Corp. (BCTX) traded nearly 12% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6008109823653589&amp;symbol=BCTX">announced</a> positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI).The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients.The survival data of patients enrolled in the study with hormone receptor-positive (HR+) metastatic breast cancer exceeds those of patients treated with the prescription medicine Trodelvy, the company said.HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients.In patients with triple negative breast cancer, the survival data was similar to patients on Trodelvy but still 70% higher than those of chemotherapy, the company said.CEO William V Williams expressed optimism about the survival benefit data.“Bria-IMT appears to be very well-tolerated,” he said, adding that the company looks forward to confirming the data in its Phase 3 study.Patients with HR+ and TNBC metastatic breast cancer have an overall survival of only a few months and limited therapeutic options.Earlier this month, BriaCell’s majority-owned subsidiary BriaPro Therapeutics Corp announced that it is developing antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques.On Stocktwits, retail sentiment around BriaCell Therapeutics rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1298/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_12_16_46_PM_png_18e64dcd73.webp" alt="BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1298" height="304"><figcaption>BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BCTX">BCTX stock</a> is down by about 52% year-to-date and by about 88% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/icad-stock-soars-merger-announcement-with-radnet/chQPV8HRbOq">iCAD Stock Rockets On Merger Announcement With RadNet: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish

HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said. 

Shares of BriaCell Therapeutics Corp. rose nearly 2% on Monday afternoon, reversing earlier losses as traders reacted to promising clinical data. Trading volume surged to over 90 times the daily average of about 146,000 shares.BriaCell announced what it called an “unprecedented clinical response,” including the complete resolution of a lung metastasis in a patient with metastatic breast cancer.&nbsp;The patient, a 78-year-old woman who had failed multiple prior treatments, was the first to receive Bria-OTS, a personalized off-the-shelf immunotherapy currently being tested in a Phase 1/2a dose escalation study.At the time of enrollment on Nov. 21, 2024, she had extensive metastases, including multiple bone, lymph node, and lung lesions, according to the company.&nbsp;After receiving four Bria-OTS injections over two weeks, her lung metastasis completely disappeared, while the disease remained stable elsewhere, BriaCell said.Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.By Monday afternoon, BriaCell was among the top trending tickers on Stocktwits, with the retail messages largely optimistic.“The data on this patient is a true game changer,” wrote one trader, alleging that earlier weakness in the stock was due to short-seller manipulation.<stembedurl>https://stocktwits.com/JJBurch/message/602660557</stembedurl>Traders also noted that H.C. Wainwright more than doubled its price target on BriaCell to $32, implying a nearly 700% upside from current levels.<stembedurl>https://stocktwits.com/Jaymes11/message/602663519</stembedurl>Despite Monday’s gains, BriaCell shares remain down over 90% in the past year. Message volume on Stocktwits has more than tripled in that period, reflecting growing retail interest.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend PR Newswire VANCOUVER, BC, Dec. 2, 2024 USA...

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint...

Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 7.9%

BriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling...

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$11.49
Prev Close	$12.28
Open	$12.66
Dividend Yield	0.00%
50-Day Moving Average	$11.12
Beta	0.87
Avg. Volume	45,224.11
PE Ratio	-0.16

52-Week High	$174.00
52-Week Low	$6.00
Market Capitalization	$23.13M
EPS (Annual)	-$62.19
Price to Book	1.29
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BCTX
BriaCell Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCTX News

BCTXBriaCell Therapeutics Corp